jueves, 30 de agosto de 2018

Retinoblastoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Retinoblastoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Retinoblastoma Treatment (PDQ®)–Health Professional Version


Changes to This Summary (08/22/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that the functional status of the retinoblastoma protein (pRb) is inferred to be inactive in retinoblastoma with MYCNamplification. This suggests that inactivation of RB1 by mutation or inactive pRb is a requirement for the development of retinoblastoma, independent of MYCN amplification (cited Ewens et al. as reference 13).
Added Say et al. as reference 36.
Revised text to state that while subretinal seeds can be well controlled with intra-arterial chemotherapy, vitreous seeds may be difficult to control with intra-arterial or intravenous chemotherapy alone. Also added text to state that the addition of intravitreal chemotherapy to intravenous chemotherapy is more effective in the treatment of vitreous seeds; as with primary intra-arterial chemotherapy, control of seed dust, spheres, and clouds require progressively more cycles of intravitreal chemotherapy (cited Berry et al. as reference 45 and level of evidence 3iiiDiii).
Added Shields et al. as reference 46.
Added Say et al. as reference 10.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: August 22, 2018

No hay comentarios:

Publicar un comentario